These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30253025)

  • 1. Recurrence and cancer-specific death after adjuvant chemotherapy for Stage III colon cancer.
    Chapuis PH; Bokey E; Chan C; Keshava A; Rickard MJFX; Stewart P; Young CJ; Dent OF
    Colorectal Dis; 2019 Feb; 21(2):164-173. PubMed ID: 30253025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
    Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic outcomes after adjuvant chemotherapy with capecitabine compared to 5-fluorouracil/leucovorin for geriatric stage II colon cancer: a retrospective cohort study.
    Lee KY; Park JW; Lee KY; Cho S; Kwon YH; Kim MJ; Ryoo SB; Jeong SY; Park KJ
    Int J Colorectal Dis; 2019 Apr; 34(4):629-639. PubMed ID: 30661101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study.
    Boyle JM; Kuryba A; Cowling TE; van der Meulen J; Fearnhead NS; Walker K; Braun MS; Aggarwal A
    Int J Cancer; 2022 Jan; 150(2):335-346. PubMed ID: 34520572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
    Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
    Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
    Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.
    Shah MA; Renfro LA; Allegra CJ; André T; de Gramont A; Schmoll HJ; Haller DG; Alberts SR; Yothers G; Sargent DJ
    J Clin Oncol; 2016 Mar; 34(8):843-53. PubMed ID: 26811529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A; Casadaban L; Maker AV
    J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
    André T; Vernerey D; Mineur L; Bennouna J; Desrame J; Faroux R; Fratte S; Hug de Larauze M; Paget-Bailly S; Chibaudel B; Bez J; Dauba J; Louvet C; Lepere C; Dupuis O; Becouarn Y; Mabro M; Egreteau J; Bouche O; Deplanque G; Ychou M; Galais MP; Ghiringhelli F; Dourthe LM; Bachet JB; Khalil A; Bonnetain F; de Gramont A; Taieb J;
    J Clin Oncol; 2018 May; 36(15):1469-1477. PubMed ID: 29620995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
    Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
    Meyerhardt JA; Shi Q; Fuchs CS; Meyer J; Niedzwiecki D; Zemla T; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Bendell JC; Kumar P; Lewis D; Tan B; Bertagnolli M; Grothey A; Hochster HS; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF
    JAMA; 2021 Apr; 325(13):1277-1286. PubMed ID: 33821899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
    Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
    JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
    Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
    Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study.
    Osawa H; Handa N; Minakata K
    Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.